Cardiff Oncology entered into a securities purchase agreement on July 14 to sell common stock and warrants to institutional investors and insiders. The offering raised about $10.05 million in gross proceeds, with institutions buying 8.57 million shares at $1.05 each and insiders buying 721,649 shares at $1.455 each. The deal closed on July 16, and the company plans to use the proceeds for working capital and general corporate purposes.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding CARDIFF ONCOLOGY INC (CRDF)?

Major stakeholders currently include BlackRock, Inc. ($6.4M), Vanguard Capital Management LLC ($4.6M), Laurion Capital Management LP ($4.3M). Based on the latest 13F filings, there are a total of 115 tracked investment funds and institutions maintaining positions in CRDF.

What is the overall institutional sentiment toward CRDF recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $37.5M, driven by 47 managers accumulating shares while 53 reduced their exposure.

Which institutions have been selling or reducing their CRDF positions?

In the latest period, 39 funds trimmed their holdings, and 14 managers completely exited their positions. The aggregate reported sell value was $40.3M.

Are there any notable investors adding CRDF to their portfolios?

Yes, buying activity remains notable. 18 institutions opened new positions in {ticker}, and 29 existing holders added to their shares. The total reported buy value for the quarter amounted to $6.7M.